title: Antiarrhythmic Effect of Either Negative Modulation or Blockade of Small Conductance Ca2+-activated K+ Channels on Ventricular Fibrillation in Guinea Pig Langendorff-perfused Heart.
abstract: During recent years, small conductance Ca-activated K (SK) channels have been reported to play a role in cardiac electrophysiology. SK channels seem to be expressed in atria and ventricles, but from a functional perspective, atrial activity is predominant. A general notion seems to be that cardiac SK channels are predominantly coming into play during arrhythmogenic events where intracellular concentration of Ca is increased. During ventricular fibrillation (VF), a surge of [Ca]i has the potential to bind to and open SK channels. To obtain mechanistic insight into possible roles of SK channels during VF, we conducted experiments with an SK channel pore blocker (ICA) and a negatively allosteric modulator (NS8395) in a Langendorff-perfused heart model. Both compounds increased the action potential duration, effective refractory period, and Wenckebach cycle length to comparable extents. Despite these similarities, the SK channel modulator was found to revert and prevent VF more efficiently than the SK channel pore blocker. In conclusion, either negative allosteric modulation of the SK channel with NS8593 is more favorable than pure channel block with ICA or the 2 compounds have different selectivity profiles that makes NS8593 more antiarrhythmic than ICA in a setting of VF.
authors.affiliation: *Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; †Acesion Pharma, Copenhagen, Denmark; ‡Lundbeck A/S, Copenhagen, Denmark; and §Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Jonas G
authors.initials: JG
authors.lastname: Diness
authors.forename: Jeppe E
authors.initials: JE
authors.lastname: Kirchhoff
authors.forename: Majid
authors.initials: M
authors.lastname: Sheykhzade
authors.forename: Thomas
authors.initials: T
authors.lastname: Jespersen
authors.forename: Morten
authors.initials: M
authors.lastname: Grunnet
mesh_terms: D015057:1-Naphthylamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000200:Action Potentials / Q000187:drug effects*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D022062:Electrophysiologic Techniques, Cardiac; D005260:Female; D006168:Guinea Pigs; D066298:In Vitro Techniques; D000067268:Isolated Heart Preparation; D026902:Potassium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051640:Small-Conductance Calcium-Activated Potassium Channels / Q000037:antagonists & inhibitors*; D014693:Ventricular Fibrillation / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: C515166:(R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine; D000889:Anti-Arrhythmia Agents; D026902:Potassium Channel Blockers; D051640:Small-Conductance Calcium-Activated Potassium Channels; D015057:1-Naphthylamine